ACST News and Press, Acasti Pharma Inc. From 09/26/23

2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...

2023-09-26 11:08:35 ET More on Acasti Pharma Seeking Alpha’s Quant Rating on Acasti Pharma Historical earnings data for Acasti Pharma Financial information for Acasti Pharma For further details see: Acasti announces $7.5M private placement equity f...

PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage ...

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage ...

2023-08-11 07:42:52 ET Acasti Pharma press release ( NASDAQ: ACST ): Q2 GAAP EPS of -$0.54. Cash and cash equivalents as of quarter end were $21.6 million; company reiterates projected cash runway to Q2 2025 For further details see: Acasti Pharma GAAP EPS of -$0.54

New leadership team singularly focused on executing GTX-104 strategy Announced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with first patient expected to be dosed prior to the end of 2023 Cash and cash equivalen...

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhag...

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients PR Newswire STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine...

2023-07-07 08:37:25 ET Canadian biopharma company Acasti Pharma ( NASDAQ: ACST ) said on Friday that it will effect a 1-for-6 reverse stock split to increase the company's per share market price and regain compliance with Nasdaq's minimum per share bid price requirement. ...

Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire LAVAL, QB , July 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodi...